twoXAR teams up with SoftBank Ventures, Andreessen Horowitz, and OS Fund to identify new treatments for patients

Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing. Using our artificial intelligence-driven drug discovery platform, we aim to find new, more effective treatments to benefit patients across therapeutic areas.

Today I am proud to share that we have assembled a group of high-quality global investors who will help us achieve this vision. Our Series A, which is led by SoftBank Ventures…

READ THE FULL POST AT MEDIUM.COM

A milestone worth celebrating

There have been a series of events that have defined the history of twoXAR. There was the lecture from Prof. Sirota on computational drug discovery that inspired me to invent. There was the encouragement from V. Paul Lee to patent my idea rather than publish an academic paper. There was the realization that Andrew M. Radin shared not only my name, but my passion for biotechnology and entrepreneurship.  There was that key moment while sailing the Charles River in the summer of 2014 when Andrew and I decided to launch this company.

More milestones followed. There was the day we received funds from our very first investor, Haya Al Ghanim. The email that told us we had been accepted to the StartX accelerator program at Stanford University. The phone call with Michigan State University’s Dr. Tim Collier where we learned our technology predicted in silico what he saw in the lab.

All along the way we’ve assembled an amazing team of scientists and engineers who continually push twoXAR’s technology forward, beyond my wildest imagination.

Today, I’m pleased to announce an exciting new milestone that will further shape our future. Andreessen Horowitz has led a $3.5M investment in twoXAR, along with the Stanford-StartX Fund and our visionary group of angel investors.

We will use these funds to grow our team, form new partnerships and further progress our drug candidates through preclinical studies. We are honored and pleased to have Andreessen Horowitz support our efforts. In addition to their investment, the team at Andreessen Horowitz, including our General Partner Vijay Pande, have signed up to help us with everything from recruiting to business development. It gives us great satisfaction to know we have a world-class organization standing behind us.

There are many more milestones, to be revealed on the road ahead. We look forward to sharing with you our success and discoveries along the way.